Task B25: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses, SARS-CoV-2

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: BRETT  HURST
Organization: UTAH STATE UNIVERSITY
Fiscal Year: 2024
Award: $206,532
Funding agency: National Institute of Allergy and Infectious Diseases

This contract provides in vitro testing of potential anti-viral agents, maintenance of viral stocks and cell lines needed to grow the viruses, and development of related assays.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Advanced Development><Anti-viral Agents><Assay><Bioassay><Biological Assay><COVID-19 virus><COVID19 virus><Cell Line><CellLine><CoV-2><CoV2><Contracting Opportunities><Contracts><Development><In Vitro><Influenza Therapeutic><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Maintenance><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory Virus><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Strains Cell Lines><Viral><Virus><Wuhan coronavirus><anti-microbial><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antimicrobial><coronavirus disease 2019 virus><coronavirus disease-19 virus><cultured cell line><developmental><flu therapeutic><hCoV19><in vitro testing><nCoV2><respiratory virus><severe acute respiratory syndrome-CoV>